Last updated: 2026-09-06 19:14:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Vanda Pharmaceuticals Inc. (VNDA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5,43, with a market capitalization of $334,36M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4,27 to $9,94. This page covers its latest market performance, valuation, price trends and company information.
$334,36M | |
$5,29 | |
$33,44 | |
$0,45 | |
$5,34 | |
396,41K | |
-- | |
-- | |
$9,94 | |
$4,27 | |
-- | |
-- |
Vanda Pharmaceuticals Inc. (VNDA) last closed at $5,34 as of 2026-09-04 23:31:00, unchanged from the previous close of $5,34.
During the latest regular trading session, VNDA traded between $0,45 and $33,44, with a volume of 396,41K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Vanda Pharmaceuticals Inc. (VNDA) moved from $5,23 to $5,43, representing a gain of 3,73% ($0,19).
The stock traded between $5,29 and $5,45 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 628,54 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 20,4%
VNDA is currently trading at $5,43, placing it 20,4% of the way from its 52-week low of $4,27 to its 52-week high of $9,94. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 533 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vanda Pharmaceuticals Inc. (VNDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.